TheraRadar
← Back
Data updated: Jun 28, 2026

METACEL PHARMS LLC

Pharma

METACEL PHARMS LLC is a pharmaceutical company focused on Neurology. Key products include OZOBAX DS.

2019
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

METACEL PHARMS LLC's Key Drugs

METACEL PHARMS LLC's core commercial portfolio centers on OZOBAX DS, spanning Neurology — its most strategically important drugs approved in the last 15 years.

METACEL PHARMS LLC's Recent FDA Approvals

New NDA/BLA approvals for METACEL PHARMS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

METACEL PHARMS LLC's Therapeutic Areas

METACEL PHARMS LLC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

METACEL PHARMS LLC's Top Competitors

METACEL PHARMS LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

METACEL PHARMS LLC Pipeline Snapshot

Active clinical trials for METACEL PHARMS LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • OZOBAX DS leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling